Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Next Science Limited
  6. News
  7. All News
    NXS   AU0000041329

NEXT SCIENCE LIMITED

(NXS)
  Report
Delayed Australian Stock Exchange  -  01:10 2022-10-06 am EDT
0.8000 AUD   +1.27%
08/26Next Science Secures License for Wound Cleaning Product in Canada
MT
08/25Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE
CI
08/24Transcript : Next Science Limited, H1 2022 Earnings Call, Aug 25, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about NEXT SCIENCE LIMITED
08/26Next Science Secures License for Wound Cleaning Product in Canada
MT
08/25Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE
CI
08/24Transcript : Next Science Limited, H1 2022 Earnings Call, Aug 25, 2022
CI
08/24Next Science Limited Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/25Next Science : Investor Presentation - Q2 2022
PU
05/27Next Science CEO to Resign Before June 30, 2023
MT
05/27Transcript : Next Science Limited - Shareholder/Analyst Call
CI
05/26Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer
CI
05/19Next Science Secures Australia, New Zealand Distributor for Wound Dressing Product
MT
05/18Next Science Limited Signed Multi-Year Distribution Agreement with Oraderm Pharmaceutic..
CI
05/10New Study Finds XPERIENCE™ No Rinse Solution Has Persistent Efficacy Against Both..
BU
05/10Next Science Xperience(Tm) No Rinse Solution Shows Persistent Efficacy Against Both Pla..
CI
04/28Australian Shares End Three-Day Losing Streak on Boost from Miners
MT
04/27Next Science Posts 31% Growth in Q1 Product Revenue
MT
04/27Next Science : Investor Presentation - Q1 2022
PU
04/21Next Science : 2022 Corporate Governance Statement & Appendix 4G
PU
04/21Next Science : 2022 agm
PU
03/21Next Science Completes Share Purchase Plan; Shares Up 3%
MT
03/21Next Science : Successful completion of Share Purchase Plan
PU
03/03Next Science Opens Nearly $4 Million Share Purchase Plan
MT
03/01Next Science : Application for quotation of securities - NXS
PU
02/27Transcript : Next Science Limited, 2021 Earnings Call, Feb 28, 2022
CI
02/23Next Science : Proposed issue of securities - NXS
PU
02/22Next Science : Appendix 4E / FY21 Financial Statements
PU
02/22Next Science Limited Reports Earnings Results for the Full Year Ended December 31, 2021
CI
01/31Next Science : Application for quotation of securities - NXS
PU
01/30Next Science : Investor Presentation - Q4 FY21
PU
01/30Next Science Limited Signs Sales & Distribution Relationship Agreement with Zimmer, Inc
CI
2021Next Science Secures Australian Regulatory Clearance for Surgical Cleanser Product
MT
2021Next Science Limited's Xperiencetm Cleared by TGA for Sale in Australia
CI
2021TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Re..
CI
2021TELA Bio Receives Exclusive Rights to Sell Next Science Antimicrobial Surgical Wash in ..
MT
2021Next Science Signs Distribution Deal for Antimicrobial Cleaning Product
MT
2021Next Science Limited Signs Multi-Year Distribution Agreement with Tela Bio, Inc
CI
2021Transcript : Next Science Limited, H1 2021 Earnings Call, Aug 30, 2021
CI
2021Next Science Limited Announces Half Year Report for the Six Months Ended 30 June 2021
CI
2021Next Science : to Exhibit Surgical Product Portfolio at AAOS 2021
BU
2021Next Science : Begins U.S. Clinical Trial for XPERIENCE No Rinse Antimicrobial Solution
BU
2021Next Science Limited Begins U.S. Clinical Trial for XPERIENCE No Rinse Antimicrobial So..
CI
2021Next Science : Revenue Soars 271% in H1; Shares Rise 5%
MT
2021Next Science : Product Featured in Lifetime Channel Program on Treating Chronic Wounds
BU
2021Next Science : Revises Revenue Guidance for H1 CY2021
MT
2021Next Science Limited Provides Revenue Guidance for the First Half of 2021
CI
2021Next Science : Antimicrobial Wound Gel Gets Sale Clearance from Australian ..
MT
2021Next Science Limited Receives Approval for BlastX from Therapeutic Goods Administration..
CI
2021Transcript : Next Science Limited - Shareholder/Analyst Call
CI
2021Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA
CI
2021Next Science : 's XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA
BU
2021Australian Shares Post Moderate Loss Amid Lockdown in Some Western Australian Areas
MT
2021Next Science : Receives FDA Clearance for Surgical Antimicrobial Product; S..
MT
2021Next Science Limited Announces XPerience No Rinse Antimicrobial Solution Cleared by FDA..
CI
202172,847,808 Ordinary Shares of Next Science Limited are subject to a Lock-Up Agreement E..
CI
20215,850,000 Options of Next Science Limited are subject to a Lock-Up Agreement Ending on ..
CI
2021Next Science Limited Announces Changes to Board of Directors
CI
2021Next Science Limited(ASX:NXS) dropped from S&P/ASX All Ordinari..
CI
2021Transcript : Next Science Limited, 2020 Earnings Call, Feb 23, 2021
CI
2021Next Science : Net Loss Contracts in FY20
MT
2021Next Science Limited Announces Consolidated Earnings Results for the Year Ended Decembe..
CI
2021REUTERS NEXT-Science must determine company climate targets, say executives
RE
2020Next Science : Lands CE Mark in Europe for Antimicrobial Wound Gel BlastX; ..
MT
2020Next Science Limited Receives CE Mark Approval for BlastX
CI
2020Next Science : and 3M Donate $300,000 of Breakthrough Wound Treatment to Jacksonville-Area..
BU
2020Next Science : 3M Decide Not to Renew BlastX Distribution Contract; Shares ..
MT
2020Next Science Limited Announces Non-Renewal of Distribution Agreement With 3M
CI
2020Transcript : Next Science Limited - Shareholder/Analyst Call
CI
2020Next Science : and 3M Donate $300,000 of Breakthrough Wound Treatment to New Jersey Nursin..
BU
2020Next Science Limited(ASX:NXS) dropped from S&P Global BMI Index
CI
2020Next Science Limited Announces Update on XPerience FDa Approval Process
CI
2020Transcript : Next Science Limited, H1 2020 Earnings Call, Aug 26, 2020
CI
2020Next Science Limited Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020Next Science Limited Receives Therapeutic Goods Administration Approval for Bactisure S..
CI
2020Next Science Limited(ASX:NXS) added to S&P/ASX All Ordinaries I..
CI
2020Next Science Limited(ASX:NXS) added to S&P/ASX Emerging Compani..
CI
2020Transcript : Next Science Limited - Shareholder/Analyst Call
CI
2020Next Science Limited Reports Audited Consolidated and Parent Earnings Results for the Y..
CI
1  2Next
Upcoming event on NEXT SCIENCE LIMITED